Novan

    OverviewSuggest Edit

    Novan is a clinical-stage biotechnology company focused on leveraging nitric oxide’s natural antiviral and immunomodulatory mechanisms of action to treat dermatological and oncovirus-mediated diseases. It develops NITRICIL technology that allows the control of the level of nitric oxide storage, the rate of release, and the molecule size for targeted delivery.
    TypePrivate
    Founded2008
    HQNC, US
    Websitenovan.com
    Employee Ratings2.2

    Latest Updates

    Employees (est.) (Jul 2021)41
    Share Price (Jul 2021)$8
    Cybersecurity ratingAMore

    Key People/Management at Novan

    Carri Geer

    Carri Geer

    SVP, Chief Technology Officer
    John M. Gay

    John M. Gay

    Chief Financial Officer
    W. Kent Geer

    W. Kent Geer

    Lead Independent Director
    Paula Brown Stafford

    Paula Brown Stafford

    President and Chief Executive Officer, Director
    Show more

    Novan Office Locations

    Novan has an office in Durham
    Durham, NC, US
    4020 Stirrup Creek Dr #110
    Show all (2)

    Novan Financials and Metrics

    Summary Metrics

    Founding Date

    2008

    Novan Cybersecurity Score

    Cybersecurity ratingPremium dataset

    A

    95/100

    SecurityScorecard logo

    Novan Online and Social Media Presence

    Embed Graph

    Novan News and Updates

    Novan Announces Last Patient Visit at Week 24 in B-SIMPLE4 Pivotal Phase 3 Trial of SB206 in Patients with Molluscum Contagiosum

    – Company previously reported positive topline efficacy and favorable safety data at Week 12 from B-SIMPLE4 in June 2021, with primary endpoint achieving statistical significance with p-value less than 0.0001 and no serious adverse events related to treatment with SB206 –

    Novan Announces Inclusion in Russell Microcap® Index

    DURHAM, N.C., June 24, 2021 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that as part of the annual reconstitution of the Russell stock indexes, Novan has been selected to join the Russell Microcap® Index, effective after the U.S. market close on June …

    Thinking about buying stock in Wells Fargo, ContextLogic, Novan, Intel Corp, or Edesa Biotech?

    NEW YORK, June 18, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for WFC, WISH, NOVN, INTC, and EDSA. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

    Thinking about buying stock in Citius Pharmaceuticals, New Oriental Education, Cellect Biotechnology, Novan, or Seanergy Maritime?

    NEW YORK, June 17, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CTXR, EDU, APOP, NOVN, and SHIP. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

    Novan Announces Pricing of $40 Million Public Offering of Common Stock

    DURHAM, N.C., June 17, 2021 (GLOBE NEWSWIRE) -- Novan, Inc. (the “Company" or "Novan") (NASDAQ:NOVN) today announced the pricing of the Company's previously announced underwritten public offering (the “Offering”) of 3,636,364 shares of common stock at a public offering price of $11.00 per share fo…

    Thinking about buying stock in ContextLogic, BlackBerry, Enochian Biosciences, Novan, or Recon Technology?

    NEW YORK, June 14, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for WISH, BB, ENOB, NOVN, and RCON. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....
    Show more

    Novan Blogs

    Novan Announces Closing of $40 Million Public Offering of Common Stock

    DURHAM, N.C., June 21, 2021 (GLOBE NEWSWIRE) -- Novan, Inc. (the “Company" or "Novan") (NASDAQ:NOVN) today announced the closing of the Company's previously announced underwritten public offering (the “Offering”) of 3,636,364 shares of common stock at a public offering price of $11.00 per share.

    Novan Announces Proposed Public Offering of Common Stock

    DURHAM, N.C., June 16, 2021 (GLOBE NEWSWIRE) -- Novan, Inc. (the “Company” or “Novan”) (NASDAQ: NOVN) today announced a proposed underwritten public offering of its common stock (the “Offering”). All shares to be sold in the Offering will be sold by Novan.

    Novan Announces 1-for-10 Reverse Stock Split

    Novan Announces 1-for-10 Reverse Stock Split Content Import Tue, 05/25/2021 - 08:01 Novan Announces 1-for-10 Reverse Stock Split May 25, 2021 at 8:01 AM EDT This release is a backfill from a News Wire Press Releases …

    Novan Reports First Quarter 2021 Financial Results and Provides Corporate Update

    – Topline efficacy results for ongoing Phase 3 study evaluating SB206 as a treatment for molluscum on track for targeted readout before the end of Q2 2021 – – Preclinical program underway evaluating SB019 with berdazimer sodium as a potential intranasal therapy for COVID-19, with results targeted

    Novan to Present Clinical Data at Annual Meeting of the Society for Investigative Dermatology

    Novan to Present Clinical Data at Annual Meeting of the Society for Investigative Dermatology Content Import Thu, 04/22/2021 - 09:01 Novan to Present Clinical Data at Annual Meeting of the Society for Investigative Dermatology April 22, 2021 at 9:01 AM EDT Thi…

    Novan Bolsters Commercialization Expertise with Election of Steven D. Skolsky to Board of Directors

    – Recognized healthcare and life science industry leader with over 35 years of international product development, strategy and commercialization experience – MORRISVILLE, N.C., March 02, 2021 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced the election of
    Show more

    Novan Frequently Asked Questions

    • When was Novan founded?

      Novan was founded in 2008.

    • Who are Novan key executives?

      Novan's key executives are Carri Geer, John M. Gay and W. Kent Geer.

    • How many employees does Novan have?

      Novan has 41 employees.

    • Who are Novan competitors?

      Competitors of Novan include Memo Therapeutics, Accellix and BioMillenia.

    • Where are Novan offices?

      Novan has an office in Durham.

    • How many offices does Novan have?

      Novan has 2 offices.